Health

Eli Lilly, Johnson & Johnson Innovation – JJDC, Pfizer Ventures and Alexandria Venture Investments all returned for the $26m second tranche of the immunobiology therapy developer’s series A round.

JPMorgan Chase and Salesforce Ventures took part in financial services provider Propel's $50m series B round while prayer app developer Glorify closed its second $40m round in three months.

Returning investor GV returned for a round which hiked the clinical data software provider's overall funding to over $470m.

Illumina Ventures was among the investors in the Baidu-backed diagnostics tool developer’s latest round, boosting its overall funding to $111m.

Banking software provider Zeta netted $30m from investors including Mastercard at a $1.5bn valuation while drug development services provider Staq Pharma closed its series C round.

The Brii Biosciences-backed lung diease drug developer will use the proceeds from the offering to advance its epetraborole drug candidate and expand into Japan.

The microbiome therapeutics developer, which was spun out of Wellcome Sanger Institute, completed a $66.6m round co-led by Tencent

Nationwide’s strategic investment arm helped the clinical data sharing platform boost its overall funding to $80m.

The corporate venturing industry is pushing towards a 50:50 split in senior investor roles.

STV co-led a $54m extension lifting BNPL service Tabby's series B round to $104m while online seafood marketplace Captain Fresh doubled its valuation to $500m in a $50m series C.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.